{"content":"<li class=\"n-box-item date-title\" data-end=\"1489035599\" data-start=\"1488949200\" data-txt=\"Sunday, December 22, 2019\">Wednesday, March  8, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3249776\" data-ts=\"1489013291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMTC\" target=\"_blank\">SMTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249776-semtechplus-6_3-q4-2017-outlook-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semtech +6.3%; Q4 2017, outlook positive</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3249729-semtech-beats-0_02-beats-revenue\" target=\"_blank\">Q4 2017 results</a></strong> &ndash; revenue $141.8M (+18% Y/Y,&nbsp;<font color='green'>$3.43M above estimates</font>), EPS $0.37 (<font color='green'>$0.02 above estimates</font>), net income $24.5M, gross margin 60.5%, operating expense $52.2M, operating margin 23.7%</li><li><strong>Q1 2018 projections</strong> &ndash; revenue $142M-$150M (<a href=\"https://finance.yahoo.com/quote/SMTC/analysts?p=SMTC\" target=\"_blank\">consensus $141.42M</a>), EPS $0.39-$0.43 (consensus $0.36), gross margin 60%-61%, SG&amp;A expense $26.5M-$27.5M, R&amp;D expense $23.5M-$24.5M, interest and other expense $2.3M, tax rate 20%-24%</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>) $36.45</li><li><a href=\"https://seekingalpha.com/pr/16766016-semtech-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Press release</a> / <a href=\"http://edge.media-server.com/m/p/jpkjm7se\" target=\"_blank\">conference call</a> / <a href=\"https://seekingalpha.com/filing/3451908\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249776\" data-linked=\"Semtech +6.3%; Q4 2017, outlook positive\" data-tweet=\"$SMTC - Semtech +6.3%; Q4 2017, outlook positive https://seekingalpha.com/news/3249776-semtechplus-6_3-q4-2017-outlook-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3249776-semtechplus-6_3-q4-2017-outlook-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249771\" data-ts=\"1489012775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249771-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a> <font color='green'>+13.6%</font>. <a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/LPI' title='Laredo Petroleum Holdings, Inc.'>LPI</a> <font color='green'>+2.8%</font>. <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='red'>-27.3%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='red'>-14.0%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/SFS' title='Smart & Final Stores'>SFS</a> <font color='red'>-2.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249771\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ELF $SMTC $LPI - After Hours Gainers / Losers https://seekingalpha.com/news/3249771-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3249771-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249770\" data-ts=\"1489012651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTL\" target=\"_blank\">CMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249770-comtech-telecomplus-4_7-on-fiscal-q2-beats-upbeat-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comtech Telecom +4.7% on fiscal Q2 beats, upbeat profit guidance</a></h4><ul>   <li>Comtech Telecommunications (NASDAQ:<a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a>) is <font color='green'>up 4.7%</font> after hours following <a href=\"https://seekingalpha.com/news/3249717-comtech-telecommunications-beats-0_12-beats-revenue\" target=\"_blank\">fiscal Q2 earnings</a> that beat expectations and guided to higher-than-expected profit for the year.</li>    <li>Revenues nearly doubled thanks to last February's acquisition of TeleCommunication Systems. EBITDA, including a $10M intellectual property litigation settlement, was $13.5M (vs. $10.4M expected).</li>    <li>Book-to-bill ratio was 0.94 (boosted by a 1.22 in its Commercial Solutions segment). Backlog as of Jan. 31 was $453.3M.</li>    <li>In updated guidance for fiscal 2017, it's set revenue targets to $570M-$580M (down from $600M and below consensus for $595.4M), and set GAAP EPS goals at $0.68 (including $0.27 tied to the favorable settlement, and vs. an expected $0.30). It's forecast EBITDA for $70M vs. consensus of $67.3M.</li>    <li><a href=\"http://www.comtechtel.com/eventdetail.cfm?EventID=180696\" target=\"_blank\">Conference call</a> to come tomorrow at 8:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16765986-comtech-telecommunications-corp-announces-results-second-quarter-fiscal-2017-updates-fiscal\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3249770\" data-linked=\"Comtech Telecom +4.7% on fiscal Q2 beats, upbeat profit guidance\" data-tweet=\"$CMTL - Comtech Telecom +4.7% on fiscal Q2 beats, upbeat profit guidance https://seekingalpha.com/news/3249770-comtech-telecomplus-4_7-on-fiscal-q2-beats-upbeat-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3249770-comtech-telecomplus-4_7-on-fiscal-q2-beats-upbeat-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249769\" data-ts=\"1489011835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLNT\" target=\"_blank\">PLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249769-planet-fitness-down-2_4-on-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Planet Fitness down 2.4% on share sale</a></h4><ul><li>Certain stockholders <a href=\"https://seekingalpha.com/pr/16766008-planet-fitness-inc-announces-secondary-offering-class-common-stock-selling-stockholders\" target=\"_blank\">have put 15M shares</a> up for sale. The company will receive no proceeds from the offering.</li><li><a href='https://seekingalpha.com/symbol/PLNT' title='Planet Fitness'>PLNT</a>&nbsp;<font color='red'>-2.4%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3249769\" data-linked=\"Planet Fitness down 2.4% on share sale\" data-tweet=\"$PLNT - Planet Fitness down 2.4% on share sale https://seekingalpha.com/news/3249769-planet-fitness-down-2_4-on-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3249769-planet-fitness-down-2_4-on-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249767\" data-ts=\"1489011515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249767-tg-therapeutics-raising-capitalminus-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics raising capital, -3% after hours</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16765904-tg-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">size of the equity offering</a> isn't noted. It will include a greenshoe to the underwriter Jefferies for up to another 15% of the shares sold.</li><li><a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a><font color='red'> -2.9%</font>&nbsp;after hours</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248760-tg-therapeuticss-blood-cancer-candidate-ublituximab-successful-late-state-study-shares-jump\" target=\"_blank\">TG Therapeutics's blood cancer candidate ublituximab successful in late-state study; shares jump 53% premarket</a> (March 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249767\" data-linked=\"TG Therapeutics raising capital, -3% after hours\" data-tweet=\"$TGTX - TG Therapeutics raising capital, -3% after hours https://seekingalpha.com/news/3249767-tg-therapeutics-raising-capitalminus-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3249767-tg-therapeutics-raising-capitalminus-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249758\" data-ts=\"1489010924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGI\" target=\"_blank\">SBGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249758-sinclair-broadcast-sets-up-offering-of-12m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinclair Broadcast sets up offering of 12M shares</a></h4><ul>     <li>Sinclair Broadcast Group (<a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a> <font color='red'>-1.7%</font>) has set a <a href=\"https://seekingalpha.com/pr/16765886-sinclair-broadcast-group-announces-public-offering-class-common-stock\" target=\"_blank\">public offering</a> of its Class A common stock.</li>     <li>The company will sell 12M primary shares, with a 30-day option to buy up to an additional 1.8M shares on the same terms.</li>     <li>Proceeds will go to \"fund future potential acquisitions\" and for general purposes.</li>     <li>Joint book-runners are Wells Fargo, J.P. Morgan and RBC Capital Markets.</li>     <li>Shares are flat at $41.60 in some choppy aftermarket trades.</li>   <li><b>Updated 5:18 p.m.:</b> Shares are <font color='red'>off 1.9%</font> in postmarket trade.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3249758\" data-linked=\"Sinclair Broadcast sets up offering of 12M shares\" data-tweet=\"$SBGI - Sinclair Broadcast sets up offering of 12M shares https://seekingalpha.com/news/3249758-sinclair-broadcast-sets-up-offering-of-12m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3249758-sinclair-broadcast-sets-up-offering-of-12m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249757\" data-ts=\"1489010831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249757-spectrum-pharma-q4-top-line-down-30-net-loss-widens-shares-down-15-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after hours</a></h4><ul><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) <a href=\"https://seekingalpha.com/pr/16765912-spectrum-pharmaceuticals-reports-fourth-quarter-2016-full-year-2016-financial-results\" target=\"_blank\">Q4 results </a>($M): Total Revenues: 35.2 (-30.0%); Product Sales: 32.2 (-7.5%).</li><li>Net Loss: (17.4) (-314.3%); Non-GAAP Net Loss: (8.1) (-76.1%); Loss/Share: (0.22) (-266.7%); Non-GAAP Loss/Share: (0.10) (-42.9%).</li><li>BLA filing in U.S. for ROLONTIS expected in 2018.</li><li>Results from investigator-sponsored study of poziotinib in NSCLC expected by year end.</li><li>Special protocol assessment received from FDA related to Phase 3 study of Qapzola in non-muscle invasive bladder cancer.</li><li>Shares are off&nbsp;<font color='red'>15%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249757\" data-linked=\"Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after hours\" data-tweet=\"$SPPI - Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after hours https://seekingalpha.com/news/3249757-spectrum-pharma-q4-top-line-down-30-net-loss-widens-shares-down-15-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3249757-spectrum-pharma-q4-top-line-down-30-net-loss-widens-shares-down-15-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249735\" data-ts=\"1489008895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249735-dizzying-fall-for-tailored-brands-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dizzying fall for Tailored Brands after earnings</a></h4><ul>     <li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>) craters after <a href=\"https://seekingalpha.com/pr/16765981-tailored-brands-inc-reports-fiscal-2016-fourth-quarter-full-year-results\" target=\"_blank\">Q4 results</a> miss estimates by a wide margin.</li><li>Comparable sales fell 5.2% for the K&amp;G brand during the quarter and dropped 2.2% for the Jos. A Bank chain.</li>     <li>\"The challenging retail environment resulted in soft traffic across our retail brands, which drove lower than anticipated fourth quarter and full year net sales and gross margins,\" says CEO Doug Ewert.</li>     <li>The company expects 2017 EPS of $1.45 to $1.75.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249716-tailored-brands-misses-0_07-misses-revenue\" target=\"_blank\">Tailored Brands misses by $0.07, misses on revenue</a> (March 8)</li><li>TLRD&nbsp;<font color='red'>-22.55%</font>&nbsp;AH to $18.10.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249735\" data-linked=\"Dizzying fall for Tailored Brands after earnings\" data-tweet=\"$TLRD - Dizzying fall for Tailored Brands after earnings https://seekingalpha.com/news/3249735-dizzying-fall-for-tailored-brands-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3249735-dizzying-fall-for-tailored-brands-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249731\" data-ts=\"1489008790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RATE\" target=\"_blank\">RATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249731-bankrateminus-6_9-q4-profits-revenues-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bankrate -6.9% as Q4 profits, revenues miss</a></h4><ul>   <li>Bankrate (<a href='https://seekingalpha.com/symbol/RATE' title='Bankrate Inc.'>RATE</a> <font color='green'>+1.6%</font>) has <font color='red'>slid 6.9%</font> after hours following misses on the top and bottom line in its <a href=\"https://seekingalpha.com/news/3249671-bankrate-misses-0_03-misses-revenue\" target=\"_blank\">Q4 earnings</a>, though net profits increased slightly on strength in its key credit cards segment.</li>    <li>Revenues were up nearly 22% and EBITDA rose 7% to $30.4M, slightly below an expected $31.4M.</li>    <li>\"We are laser-focused on continuing to scale revenue, while accelerating adjusted EBITDA growth,\" said CEO Kenneth Esterow.</li>    <li>Revenue by segment: Credit cards, $83.7M (up 32%); Banking, $26.2M (up 6%); Senior care, $5.4M (down 14%);</li>    <li>For Q1, it's guiding to revenues of $115M-$118M (above consensus for $114.2M) and EBITDA of $26M-$28M (vs. consensus for $28.2M). For the full year, it's forecasting revenues of $500M-$515M (above an expected $498.3M) and EBITDA of $122M-$129M (vs. consensus for $124.2M).</li>    <li><a href=\"http://investor.bankrate.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16765888-bankrate-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3249731\" data-linked=\"Bankrate -6.9% as Q4 profits, revenues miss\" data-tweet=\"$RATE - Bankrate -6.9% as Q4 profits, revenues miss https://seekingalpha.com/news/3249731-bankrateminus-6_9-q4-profits-revenues-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3249731-bankrateminus-6_9-q4-profits-revenues-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249722\" data-ts=\"1489008459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249722-energousminus-9-q4-2016-off-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous -9%; Q4 2016 off expectations</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3249684-energous-misses-0_21-misses-revenue\" target=\"_blank\">Q4 2016 results</a></strong> &ndash; revenue $0.13M (<font color='red'>$0.26M below estimates</font>), EPS -$0.75 (<font color='red'>$0.21 below estimates</font>), net loss $14.6M, operating expenses $14.7M ($9.7M R&amp;D, $4M general and administrative, $1M sales and marketing), adjusted EBITDA loss $10.2M, cash and cash equivalents $31.M with no debt</li><li>Energous president and CEO&nbsp;Stephen&nbsp;Rizzone: \"Energous is on track to develop and successfully commercialize a new technology that has never before been available, and that will have what we believe is a far-reaching impact on the consumer and enterprise markets. The company is working toward shipping fully commercialized WattUp chipsets, expanding its customer base, and securing FCC approval for its longer range charging solutions. We are singularly focused on building a highly relevant and valuable company for the long-term, and firmly believe we will exit this year positioned for significant, ongoing growth.\"</li><li><strong>After hours</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) $13.68</li><li><a href=\"https://seekingalpha.com/pr/16765933-energous-corporation-reports-2016-fourth-quarter-full-year-financial-results\" target=\"_blank\">Press release</a> / <a href=\"http://78449.choruscall.com/dataconf/productusers/watt/mediaframe/18505/indexr.html\" target=\"_blank\">conference call</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249722\" data-linked=\"Energous -9%; Q4 2016 off expectations\" data-tweet=\"$WATT - Energous -9%; Q4 2016 off expectations https://seekingalpha.com/news/3249722-energousminus-9-q4-2016-off-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3249722-energousminus-9-q4-2016-off-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249719\" data-ts=\"1489008066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249719-biocryst-readies-45m-equity-offering-shares-slip-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst readies $45M equity offering; shares slip 4% after hours</a></h4><ul><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) eases&nbsp;<font color='red'>4%</font>&nbsp;after hours on modestly higher volume in response to it proposed <a href=\"https://seekingalpha.com/pr/16765894-biocryst-pharmaceuticals-commences-public-offering-common-stock\" target=\"_blank\">$45M public offering</a> of common stock. Price, volume and terms have yet to be announced.</li><li>Today's close was $8.41.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249719\" data-linked=\"BioCryst readies $45M equity offering; shares slip 4% after hours\" data-tweet=\"$BCRX - BioCryst readies $45M equity offering; shares slip 4% after hours https://seekingalpha.com/news/3249719-biocryst-readies-45m-equity-offering-shares-slip-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3249719-biocryst-readies-45m-equity-offering-shares-slip-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249715\" data-ts=\"1489007973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249715-agile-therapeutics-beats-0_10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile Therapeutics beats by $0.10</a></h4><ul><li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>): Q4 EPS of -$0.18 <font color='green'>beats by $0.10</font>.</li><li><a href=\"https://seekingalpha.com/pr/16765978-agile-therapeutics-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249715\" data-linked=\"Agile Therapeutics beats by $0.10\" data-tweet=\"$AGRX - Agile Therapeutics beats by $0.10 https://seekingalpha.com/news/3249715-agile-therapeutics-beats-0_10?source=tweet\" data-url=\"https://seekingalpha.com/news/3249715-agile-therapeutics-beats-0_10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249710\" data-ts=\"1489007893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249710-amicus-launches-migalastat-in-italy-shares-ahead-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus launches migalastat in Italy; shares ahead 3% after hours</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) perks up&nbsp;<font color='green'>3%&nbsp;</font>after hours on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16765899-amicus-therapeutics-launches-galafold-migalastat-treatment-fabry-disease-italy\" target=\"_blank\">announcement </a>that it has launched Galafold (migalastat) for the long-term treatment of patients at least 16 years old with Fabry disease in Italy.</li><li>CEO John Crowley says, \"The commercial launch of Galafold in&nbsp;Italy&nbsp;is a significant milestone for the Fabry community. All Fabry patients in&nbsp;Italy&nbsp;16 years and older who have an amenable mutation will now have access to the first oral treatment as well as the first precision medicine for their Fabry disease. We believe that our successful pricing and reimbursement in&nbsp;Italy&nbsp;is a testament to the significant value of our oral precision medicine, and reflects our growing momentum with the country-by-country processes to launch Galafold throughout the EU.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3249710\" data-linked=\"Amicus launches migalastat in Italy; shares ahead 3% after hours\" data-tweet=\"$FOLD - Amicus launches migalastat in Italy; shares ahead 3% after hours https://seekingalpha.com/news/3249710-amicus-launches-migalastat-in-italy-shares-ahead-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3249710-amicus-launches-migalastat-in-italy-shares-ahead-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249713\" data-ts=\"1489007891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249713-tyrrells-powers-growth-amplify-snack-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tyrrells powers growth at Amplify Snack Brands</a></h4><ul>     <li>Amplify Snack Brands (NYSE:<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a>) reports sales growth of 91% in <a href=\"https://seekingalpha.com/pr/16765924-amplify-snack-brands-inc-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Q4</a> as the acquisition of the Tyrrell's business factored in.</li>     <li>Gross profit as a percentage of sales fell to 41.5% vs. 56.5% a year ago. Adjusted EBITDA was 26.6% of sales vs. 40.4% a year ago.</li>     <li>\"Our fourth quarter financial performance reflects the strong momentum for our SkinnyPop, Paqui and Oatmega brands, and the addition of Tyrrells,\" notes CEO Tom Ennis.</li>     <li>Looking ahead, Amplify expects revenue of $404M to $420M and EPS of $0.43 to $0.51.</li><li>BETR&nbsp;<font color='green'>+2.79%</font>&nbsp;AH to $9.20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249713\" data-linked=\"Tyrrells powers growth at Amplify Snack Brands\" data-tweet=\"$BETR $BETR-OLD - Tyrrells powers growth at Amplify Snack Brands https://seekingalpha.com/news/3249713-tyrrells-powers-growth-amplify-snack-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3249713-tyrrells-powers-growth-amplify-snack-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249712\" data-ts=\"1489007863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249712-tandem-diabetes-care-beats-0_17-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tandem Diabetes Care beats by $0.17, beats on revenue</a></h4><ul><li>Tandem Diabetes Care (NASDAQ:<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a>): Q4 EPS of -$0.48 <font color='green'>beats by $0.17</font>.</li><li>Revenue of $24.8M (-14.8% Y/Y) <font color='green'>beats by $2.05M</font>.</li><li>Shares <font color='green'>+11.6%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765920-tandem-diabetes-care-reports-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249712\" data-linked=\"Tandem Diabetes Care beats by $0.17, beats on revenue\" data-tweet=\"$TNDM - Tandem Diabetes Care beats by $0.17, beats on revenue https://seekingalpha.com/news/3249712-tandem-diabetes-care-beats-0_17-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3249712-tandem-diabetes-care-beats-0_17-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249698\" data-ts=\"1489007590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249698-vivus-beats-0_31-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus beats by $0.31, beats on revenue</a></h4><ul><li>Vivus (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='Vivus, Inc.'>VVUS</a>): Q4 EPS of $0.54 <font color='green'>beats by $0.31</font>.</li><li>Revenue of $81.8M (+433.2% Y/Y) <font color='green'>beats by $32.98M</font>.</li><li>Shares <font color='green'>+6.7%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765955-vivus-reports-fourth-quarter-full-year-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249698\" data-linked=\"Vivus beats by $0.31, beats on revenue\" data-tweet=\"$VVUS - Vivus beats by $0.31, beats on revenue https://seekingalpha.com/news/3249698-vivus-beats-0_31-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3249698-vivus-beats-0_31-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249689\" data-ts=\"1489007455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELF\" target=\"_blank\">ELF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249689-e-l-f-beauty-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">e.l.f. Beauty beats by $0.05, beats on revenue</a></h4><ul><li>e.l.f. Beauty (NYSE:<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a>): Q4 EPS of $0.19 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $76.4M (+16.8% Y/Y) <font color='green'>beats by $1.89M</font>.</li><li>Shares <font color='green'>+10.2%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765928-e-l-f-beauty-inc-announces-fourth-quarter-full-year-2016-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249689\" data-linked=\"e.l.f. Beauty beats by $0.05, beats on revenue\" data-tweet=\"$ELF - e.l.f. Beauty beats by $0.05, beats on revenue https://seekingalpha.com/news/3249689-e-l-f-beauty-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3249689-e-l-f-beauty-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249688\" data-ts=\"1489007389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249688-amplify-snack-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amplify Snack misses by $0.01, beats on revenue</a></h4><ul><li>Amplify Snack (NYSE:<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a>): Q4 EPS of $0.09 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $88.6M (+91.1% Y/Y) <font color='green'>beats by $1.32M</font>.</li><li>Shares <font color='green'>+3%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765924-amplify-snack-brands-inc-reports-fourth-quarter-full-year-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249688\" data-linked=\"Amplify Snack misses by $0.01, beats on revenue\" data-tweet=\"$BETR $BETR-OLD - Amplify Snack misses by $0.01, beats on revenue https://seekingalpha.com/news/3249688-amplify-snack-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3249688-amplify-snack-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249683\" data-ts=\"1489007277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCOM\" target=\"_blank\">PCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249683-points-international-eps-of-0_24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Points International EPS of -$0.24</a></h4><ul><li>Points International (NASDAQ:<a href='https://seekingalpha.com/symbol/PCOM' title='Points International, Ltd.'>PCOM</a>): Q4 EPS of -$0.24 may not be comparable to consensus of $0.09.</li><li>Revenue of $82M (+2.2% Y/Y) <font color='red'>misses by $6.22M</font>.</li><li>Shares <font color='green'>+3%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765945-points-international-ltd-reports-fourth-quarter-full-year-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249683\" data-linked=\"Points International EPS of -$0.24\" data-tweet=\"$PCOM - Points International EPS of -$0.24 https://seekingalpha.com/news/3249683-points-international-eps-of-0_24?source=tweet\" data-url=\"https://seekingalpha.com/news/3249683-points-international-eps-of-0_24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249676\" data-ts=\"1489007152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TVIAQ\" target=\"_blank\">TVIAQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249676-terravia-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TerraVia beats by $0.03, beats on revenue</a></h4><ul><li>TerraVia (TVIA): Q4 EPS of -$0.20 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $4.8M (-11.1% Y/Y) <font color='green'>beats by $0.53M</font>.</li><li>Shares <font color='green'>+19%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16765913-terravia-reports-fourth-quarter-full-year-2016-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249676\" data-linked=\"TerraVia beats by $0.03, beats on revenue\" data-tweet=\"$TVIAQ - TerraVia beats by $0.03, beats on revenue https://seekingalpha.com/news/3249676-terravia-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3249676-terravia-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249670\" data-ts=\"1489006717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVX\" target=\"_blank\">CVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249670-chevron-starts-production-mafumeira-sul-project-offshore-angola\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chevron starts production at Mafumeira Sul project offshore Angola</a></h4><ul>     <li>Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='red'>-2%</font>) says its Cabinda Gulf Oil subsidiary has <a href=\"https://seekingalpha.com/pr/16764892-chevron-starts-production-mafumeira-sul-offshore-angola\" target=\"_blank\">started oil and gas production</a> from the primary production facility for its Mafumeira Sul project offshore Angola.</li>     <li>The field lies ~15 miles from the Angolan coast under 60 ft. of water and is expected to produce ~150K bbl/day of natural gas liquids and 350M cf/day of natural gas per day.</li>     <li>Initial production started last September with the ramp up to full production expected to be completed by next year.</li>     <li>CVX, through the local subsidiary, operates and owns a 39.2% stake in the Mafumeira Sul project, Sonangol holds a 41% interest, and Total (NYSE:<a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a>) and Eni (NYSE:<a href='https://seekingalpha.com/symbol/E' title='ENI S.p.A.'>E</a>) comprise the remaining 10% and 9.8% shares, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249670\" data-linked=\"Chevron starts production at Mafumeira Sul project offshore Angola\" data-tweet=\"$CVX $CVX $TOT - Chevron starts production at Mafumeira Sul project offshore Angola https://seekingalpha.com/news/3249670-chevron-starts-production-mafumeira-sul-project-offshore-angola?source=tweet\" data-url=\"https://seekingalpha.com/news/3249670-chevron-starts-production-mafumeira-sul-project-offshore-angola\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249666\" data-ts=\"1489006529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/O\" target=\"_blank\">O</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249666-rough-session-for-reits-10-year-yield-hits-2017-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough session for REITs as 10-year yield hits 2017 high</a></h4><ul><li>Helped along by a big 298K gain in February jobs reported by the ADP (the government reports on Friday), the 10-year Treasury yield is higher today by four basis points to 2.56% - pretty close to its highest level since the election.</li><li>Meanwhile on the short end, traders have priced in a 100% chance of a FOMC rate hike next week, with the next move after that coming by Labor Day (seems late given recent Fed talk).</li><li>While the S&amp;P 500 and Dow are down just modestly, and the Nasdaq positive, the <a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a> is<font color='red'> off 1.6%</font>&nbsp;and <a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a><font color='red'> 1.9%</font>&nbsp;as REITs begin to face more serious competition in the yield department.</li><li>Realty Income (<a href='https://seekingalpha.com/symbol/O' title='Realty Income Corporation'>O</a> <font color='red'>-3.7%</font>), Vereit (<a href='https://seekingalpha.com/symbol/VER' title='VEREIT Inc.'>VER</a> <font color='red'>-3.7%</font>), Omega Health (<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a> <font color='red'>-2.1%</font>), HCP (<a href='https://seekingalpha.com/symbol/HCP' title='HCP, Inc.'>HCP</a> <font color='red'>-3.1%</font>), W.P. Carey (<a href='https://seekingalpha.com/symbol/WPC' title='W.P. Carey, Inc.'>WPC</a> <font color='red'>-2.4%</font>), Essex Property (<a href='https://seekingalpha.com/symbol/ESS' title='Essex Property Trust, Inc.'>ESS</a> <font color='red'>-1.2%</font>), Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-1.6%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='red'>-2.2%</font>), Public Storage (<a href='https://seekingalpha.com/symbol/PSA' title='Public Storage'>PSA</a> <font color='red'>-1.9%</font>), Government Properties (<a href='https://seekingalpha.com/symbol/GOV-OLD' title='Government Properties Income Trust'>GOV-OLD</a> <font color='red'>-4.3%</font>), Stag Industrial (<a href='https://seekingalpha.com/symbol/STAG' title='STAG Industrial, Inc.'>STAG</a> <font color='red'>-2.7%</font>), AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='red'>-2.1%</font>), Annaly (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color='red'>-1.6%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a>, <a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a>, <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a>, <a href='https://seekingalpha.com/symbol/DRN' title='Direxion Daily Real Estate Bull 3x Shares ETF'>DRN</a>, <a href='https://seekingalpha.com/symbol/RQI' title='Cohen&Steers Quality Income Realty Fund'>RQI</a>, <a href='https://seekingalpha.com/symbol/URE' title='ProShares Ultra Real Estate ETF'>URE</a>, <a href='https://seekingalpha.com/symbol/SCHH' title='Schwab U.S. REIT ETF'>SCHH</a>, <a href='https://seekingalpha.com/symbol/ICF' title='iShares Cohen & Steers REIT ETF'>ICF</a>, <a href='https://seekingalpha.com/symbol/RWR' title='SPDR Dow Jones REIT ETF'>RWR</a>, <a href='https://seekingalpha.com/symbol/SRS' title='ProShares UltraShort Real Estate ETF'>SRS</a>, <a href='https://seekingalpha.com/symbol/RNP' title='Cohen&Steers REIT&Preferred Income Fund'>RNP</a>, <a href='https://seekingalpha.com/symbol/RFI' title='Cohen&Steers Total Return Realty Fund'>RFI</a>, <a href='https://seekingalpha.com/symbol/JRS' title='Nuveen Real Estate Income Fund'>JRS</a>, <a href='https://seekingalpha.com/symbol/KBWY' title='Invesco KBW Premium Yield Equity REIT Portfolio ETF'>KBWY</a>, <a href='https://seekingalpha.com/symbol/NRO' title='Neuberger Berman Real Estate Securities Income Fund'>NRO</a>, <a href='https://seekingalpha.com/symbol/DRV' title='Direxion Daily Real Estate Bear 3x Shares ETF'>DRV</a>, <a href='https://seekingalpha.com/symbol/RIT' title='LMP Real Estate Income Fund'>RIT</a>, <a href='https://seekingalpha.com/symbol/RIF' title='RMR Real Estate Income Fund'>RIF</a>, <a href='https://seekingalpha.com/symbol/REK' title='ProShares Short Real Estate ETF'>REK</a>, <a href='https://seekingalpha.com/symbol/DRA' title='Diversified Real Asset Income Fund'>DRA</a>, <a href='https://seekingalpha.com/symbol/FRI' title='First Trust S&P REIT Index ETF'>FRI</a>, <a href='https://seekingalpha.com/symbol/FTY' title='iShares Real Estate 50 ETF'>FTY</a>, <a href='https://seekingalpha.com/symbol/FREL' title='Fidelity MSCI Real Estate Index ETF'>FREL</a>, <a href='https://seekingalpha.com/symbol/LRET' title='ETRACS Monthly Pay 2xLeveraged MSCI US REIT Index ETN'>LRET</a>, <a href='https://seekingalpha.com/symbol/PSR' title='Inv Act Man Exg Shs'>PSR</a>, <a href='https://seekingalpha.com/symbol/WREI' title='Invesco Wilshire U.S. Real Estate Investment Trust ETF'>WREI</a>, <a href='https://seekingalpha.com/symbol/XLRE' title='Real Estate Select Sector SPDR ETF'>XLRE</a>, <a href='https://seekingalpha.com/symbol/IARAX' title='Invesco Real Estate Fund A'>IARAX</a>, <a href='https://seekingalpha.com/symbol/RORE' title='Hartford Multifactor REIT ETF'>RORE</a>, <a href='https://seekingalpha.com/symbol/USRT' title='iShares Core U.S. REIT ETF'>USRT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249666\" data-linked=\"Rough session for REITs as 10-year yield hits 2017 high\" data-tweet=\"$O $IYR $VNQ - Rough session for REITs as 10-year yield hits 2017 high https://seekingalpha.com/news/3249666-rough-session-for-reits-10-year-yield-hits-2017-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3249666-rough-session-for-reits-10-year-yield-hits-2017-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249664\" data-ts=\"1489005442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249664-randgold-resources-downgraded-pretium-resources-upgraded-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Randgold Resources downgraded, Pretium Resources upgraded at RBC</a></h4><ul><li>Randgold Resources (<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='red'>-1.6%</font>) is <a href=\"http://blogs.barrons.com/emergingmarketsdaily/2017/03/08/randgold-sinks-on-rbc-downgrade/?mod=BOL_hp_blog_stw\" target=\"_blank\">downgraded</a> to Underperform from Sector Perform at RBC Capital, which sees valuation edging back from peak levels.</li><li>As GOLD's current growth phase comes to an end, with uncertainty  remaining on the next value creation source and an equity that RBC  views as more than fairly priced, the firm expects the stock to underperform  peers.</li><li>At the same time, RBC upgrades Pretium Resources (<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+2.6%</font>) to Outperform from Sector Perform, expecting the stock to re-rate over the coming months as  the Brucejack project successfully ramps up following commissioning in Q2.</li><li>With  convertible financing closed, the firm thinks PVG has more than  sufficient funds to bring Brucejack into production.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249664\" data-linked=\"Randgold Resources downgraded, Pretium Resources upgraded at RBC\" data-tweet=\"$GOLD $GOLD $PVG - Randgold Resources downgraded, Pretium Resources upgraded at RBC https://seekingalpha.com/news/3249664-randgold-resources-downgraded-pretium-resources-upgraded-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3249664-randgold-resources-downgraded-pretium-resources-upgraded-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249663\" data-ts=\"1489005147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249663-snap-rebounds-7-tepper-fan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap rebounds 7%; Tepper a fan</a></h4><ul><li>Appearing on CNBC this morning, a generally bullish (on markets overall) David Tepper <a href=\"http://thereformedbroker.com/2017/03/08/david-tepper-comes-alive/?utm_source=dlvr.it&amp;utm_medium=twitter\" target=\"_blank\">says he was a buyer</a> of Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) on the IPO. Tepper personally isn't a user, but his daughter is, and the demographics (the \"anti-Facebook\") are interesting to him.</li><li>Tepper does say he sold some shares when the stock popped into the high $20s just after the IPO, but he'd be a buyer again if the price falls back towards the offering level ($17).</li><li>Snap&nbsp;<font color='green'>+6.9%</font>&nbsp;to $22.92</li></ul><div class=\"tiny-share-widget\" data-id=\"3249663\" data-linked=\"Snap rebounds 7%; Tepper a fan\" data-tweet=\"$SNAP - Snap rebounds 7%; Tepper a fan https://seekingalpha.com/news/3249663-snap-rebounds-7-tepper-fan?source=tweet\" data-url=\"https://seekingalpha.com/news/3249663-snap-rebounds-7-tepper-fan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249661\" data-ts=\"1489004534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249661-puma-bio-claws-back-from-roche-data-stoked-drop-shares-up-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Bio claws back from Roche data-stoked drop; shares up 12%</a></h4><ul><li>Last Thursday's nearly 14% plunge in Puma Biotechnology (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+11.9%</font>) is now a memory. The sell-off was stoked by Roche's announcement of positive late-stage data on Perjeta (pertuzumab) in HER2+ breast cancer. The negative connotations for Puma's HER2+ breast cancer candidate neratinib (PB272) had investors racing to the exits. No more. Shares have rallied over 40% since then.</li><li>Stifel's Thomas Shrader: \"People are feeling they overreacted. Puma's neratinib remains a good drug for patients that have progressed on other treatments and works best in HR-positive patients, where Perjeta + Herceptin appear weakest.\" He rates Puma a Buy.</li><li>Citigroup is also bullish, advising clients to \"buy the drop.\" RBC begs to differ, however, saying neratinib is having \"a very tough time being commercially relevant.\"</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248119-puma-bio-sinks-roche-announces-positive-perjeta-data-her2-plus-breast-cancer-shares-25\" target=\"_blank\">Puma Bio sinks after Roche announces positive Perjeta data in HER2+ breast cancer; shares off 25% premarket</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249661\" data-linked=\"Puma Bio claws back from Roche data-stoked drop; shares up 12%\" data-tweet=\"$PBYI - Puma Bio claws back from Roche data-stoked drop; shares up 12% https://seekingalpha.com/news/3249661-puma-bio-claws-back-from-roche-data-stoked-drop-shares-up-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3249661-puma-bio-claws-back-from-roche-data-stoked-drop-shares-up-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249658\" data-ts=\"1489003247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249658-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PRSS' title='CafePress'>PRSS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTC:SOFO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a> <font color='red'>-9%</font>. HTCO <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OCC' title='Optical Cable Corporation'>OCC</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249658\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$PRSS $EXTR $MOMO - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3249658-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3249658-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249656\" data-ts=\"1489002880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249656-met-coal-stocks-to-see-pressure-on-china-seaport-global-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Met coal stocks to see more pressure on China, Seaport Global says</a></h4><ul><li>Met coal exposed stocks likely will see further pressure as China said it will  avoid coal mining limits if prices remain &ldquo;reasonable,&rdquo; according to Seaport Global&rsquo;s  Head of Energy Trading.</li><li>Speculation says China will reinstate its 276-day operating limit at the end of the Chinese  winter, with the news likely to impact met coal stocks such as Arch Coal (<a href='https://seekingalpha.com/symbol/ARCH' title='Arch Coal Inc'>ARCH</a> <font color='red'>-3.1%</font>) and Natural Resource Partners (<a href='https://seekingalpha.com/symbol/NRP' title='Natural Resource Partners LP'>NRP</a> <font color='green'>+1.6%</font>).</li><li>Among the world's top coking coal producers are BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-4%</font>), Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-1.4%</font>), Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-1.8%</font>) and Anglo American (<a href='https://seekingalpha.com/symbol/AAUKF' title='Anglo American plc'>OTCQX:AAUKF</a>, <a href='https://seekingalpha.com/symbol/AAUKY' title='Anglo American plc ADR'>OTCPK:AAUKY</a>).</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3249656\" data-linked=\"Met coal stocks to see more pressure on China, Seaport Global says\" data-tweet=\"$ARCH $ARCH $NRP - Met coal stocks to see more pressure on China, Seaport Global says https://seekingalpha.com/news/3249656-met-coal-stocks-to-see-pressure-on-china-seaport-global-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3249656-met-coal-stocks-to-see-pressure-on-china-seaport-global-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249655\" data-ts=\"1489002824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249655-biocryst-pharma-up-nearly-10-after-jmp-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst Pharma up nearly 10% after JMP note</a></h4><ul><li>BioCryst's (<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+9.5%</font>) BCX7353 led to a clinically meaningful reduction in hereditary angioedema attacks, says analyst&nbsp;Liisa Bayko, citing HAE expert Dr. Marc Riedl.</li><li>Unwanted side effects from the Feb. 27 APeX-1 data are \"partially muddled,\" she says, as patients may not be able to distinguish between GI side effects and HAE attacks.</li><li>The stock's now&nbsp;<font color='green'>higher by more than 50%</font>&nbsp;since those results.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3249655\" data-linked=\"BioCryst Pharma up nearly 10% after JMP note\" data-tweet=\"$BCRX - BioCryst Pharma up nearly 10% after JMP note https://seekingalpha.com/news/3249655-biocryst-pharma-up-nearly-10-after-jmp-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3249655-biocryst-pharma-up-nearly-10-after-jmp-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249652\" data-ts=\"1489001837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249652-cienaminus-8_4-post-earnings-wells-fargo-dougherty-company-reiterate-bullishly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ciena -8.4% post-earnings; Wells Fargo, Dougherty &amp; Company reiterate bullishly</a></h4><ul><li>Considering <a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/08/ciena-sinks-8-on-disappointing-q1-earnings/\" target=\"_blank\">\"moderate\" revenue shortfall</a> as likely lending to disappointing sentiment, analyst Jess Lubert (Wells Fargo) nevertheless suggests positive demand trends across the majority of key regions (excluding Latin America) and product segments support firm's thesis 100G metro upgrades, data center interconnect prospects and packet networking deployments will generate sound sales trends in FY 2017. Restates Outperform, $30-$32 valuation range.</li><li>Reissuing at Buy and $26 target, analyst&nbsp;Catharine&nbsp;Trebnick attributes revenue misstep to Global Services softness (-18% sequentially), while noting revenue outlook going forward is largely in line with firm's and consensus estimates.</li><li>Ciena (NASDAQ:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) $23.96.</li><li>Earlier (March 8, 2017): <a href=\"https://seekingalpha.com/news/3249547-ciena-minus-3-percent-premarket-q1-2017-estimates-q2-revenue-forecast-midpoint\" target=\"_blank\">Ciena -3% pre-market; Q1 2017 off estimates, Q2 revenue forecast midpoint over</a>&nbsp;/ <a href=\"https://seekingalpha.com/article/4053250-cienas-cien-ceo-gary-smith-q1-2017-results-earnings-call-transcript\" target=\"_blank\">earnings call transcript</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249652\" data-linked=\"Ciena -8.4% post-earnings; Wells Fargo, Dougherty &amp; Company reiterate bullishly\" data-tweet=\"$CIEN - Ciena -8.4% post-earnings; Wells Fargo, Dougherty &amp; Company reiterate bullishly https://seekingalpha.com/news/3249652-cienaminus-8_4-post-earnings-wells-fargo-dougherty-company-reiterate-bullishly?source=tweet\" data-url=\"https://seekingalpha.com/news/3249652-cienaminus-8_4-post-earnings-wells-fargo-dougherty-company-reiterate-bullishly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249647\" data-ts=\"1489000540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249647-nickel-posts-biggest-two-day-loss-since-2015-on-ore-export-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nickel posts biggest two-day loss since 2015 on ore export plan</a></h4><ul><li>Nickel prices concluded their biggest two-day loss since 2015</a> after PT Aneka Tambang, a top Indonesian nickel producer, said it is taking steps to resume low-grade ore exports.</li><li>Nickel settled 4.2% lower at $10,200/ton on the LME, and dropped 8.1% in two days, the most since August 2015.</li><li>&ldquo;Reports that Indonesia may finally allow nickel ore imports after a  three-year ban caught a long market badly offsides,\" BMO Capital says. &ldquo;Stops were triggered that drove nickel lower in high volume trade.\"</li><li>Relevant tickers: <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-3.8%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1.8%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-1.8%</font>.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3249647\" data-linked=\"Nickel posts biggest two-day loss since 2015 on ore export plan\" data-tweet=\"$VALE $VALE $BHP - Nickel posts biggest two-day loss since 2015 on ore export plan https://seekingalpha.com/news/3249647-nickel-posts-biggest-two-day-loss-since-2015-on-ore-export-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3249647-nickel-posts-biggest-two-day-loss-since-2015-on-ore-export-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249645\" data-ts=\"1489000258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249645-globalstar-inmarsat-teaming-up-on-selling-satellite-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar, Inmarsat teaming up on selling satellite service</a></h4><ul>   <li>Globalstar (<a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+0.7%</font>) and Inmarsat (<a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc. ADR'>OTCPK:IMASY</a> <font color='green'>+7%</font>) have the framework of a deal to <a href=\"https://seekingalpha.com/pr/16765621-globalstar-inmarsat-form-partnership-cross-sell-satellite-services\" target=\"_blank\">cross-sell satellite products and services</a>, extending the power of each into a global customer base.</li>    <li>The move would combine Globalstar's strength in low-earth orbiting satellites with Inmarsat's in geostationary birds.</li>    <li>A formal agreement is expected within weeks; both companies will operate independently otherwise.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249645\" data-linked=\"Globalstar, Inmarsat teaming up on selling satellite service\" data-tweet=\"$GSAT $GSAT $IMASY - Globalstar, Inmarsat teaming up on selling satellite service https://seekingalpha.com/news/3249645-globalstar-inmarsat-teaming-up-on-selling-satellite-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3249645-globalstar-inmarsat-teaming-up-on-selling-satellite-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249642\" data-ts=\"1488999884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249642-oil-tumbles-4-after-inventory-data-put-volume-surges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil tumbles more than 4% after inventory data; put volume surges</a></h4><ul><li>The API last night reported a whopping inventory build of more than 11M barrels, and the EIA this morning more than 8M.</li><li>Black gold is<font color='red'> lower by 4.1%</font>&nbsp;to a six-week low $50.94 per barrel.</li><li>Bloomberg takes note of 220K puts traded on the U.S. Oil Fund (<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a> <font color='red'>-4.2%</font>) today vs. the 20-day average of 47K. Call volume today is 57K.</li><li>The <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> is&nbsp;<font color='red'>down 1.9%&nbsp;</font>this session vs. the Dow and S&amp;P 500 flat.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/PXE' title='PowerShares Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='PowerShares Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/UHN' title='The United States Diesel-Heating Oil ETF, LP'>UHN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249642\" data-linked=\"Oil tumbles more than 4% after inventory data; put volume surges\" data-tweet=\"$USO $XLE $OIL - Oil tumbles more than 4% after inventory data; put volume surges https://seekingalpha.com/news/3249642-oil-tumbles-4-after-inventory-data-put-volume-surges?source=tweet\" data-url=\"https://seekingalpha.com/news/3249642-oil-tumbles-4-after-inventory-data-put-volume-surges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249640\" data-ts=\"1488999781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249640-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GNE' title='Genie Energy Ltd.'>GNE</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PPG' title='PPG Industries, Inc.'>PPG</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249640\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$GNE $PPG $SDRL - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3249640-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3249640-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249629\" data-ts=\"1488997805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249629-financials-top-5-gainers-losers-of-1-30-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:30 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/GCAP' title='GAIN Capital Holdings, Inc.'>GCAP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/STL' title='Sterling Bancorp'>STL</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NSM' title='Nationstar Mortgage Holdings'>NSM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HRZN' title='Horizon Technology Finance'>HRZN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249629\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:30 PM\" data-tweet=\"$LC $GCAP $STL - Financials - Top 5 Gainers / Losers as of 1:30 PM https://seekingalpha.com/news/3249629-financials-top-5-gainers-losers-of-1-30-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3249629-financials-top-5-gainers-losers-of-1-30-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249615\" data-ts=\"1488995207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRA\" target=\"_blank\">NTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249615-natera-under-pressure-after-q4-miss-and-sell-siders-modified-outlooks-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natera under pressure after Q4 miss and sell-siders&#39; modified outlooks; shares down 15%</a></h4><ul><li>Molecular testing firm Natera (<a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a> <font color='red'>-15.1%</font>) slumps on a 5x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/16764436-natera-reports-fourth-quarter-fiscal-year-2016-financial-results\" target=\"_blank\">Q4 miss</a> released after the close yesterday. Revenues came in at $49.3M which fell short of consensus by ~$500K and were down almost 7% yoy.</li><li>Q4 tests processed: 117K (+21.9%).</li><li><strong>2017 Guidance</strong>: Revenues: $210M - 230M; product sales: 60 -65% of revenues; cash burn: $85M - 95M.</li><li>Baird trimmed its price target to $15 (79% upside), Morgan Stanley to $19, Canaccord to $14 and Piper to $18.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249302-natera-misses-0_16-misses-revenue\" target=\"_blank\">Natera misses by $0.16, misses on revenue</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249615\" data-linked=\"Natera under pressure after Q4 miss and sell-siders&#39; modified outlooks; shares down 15%\" data-tweet=\"$NTRA - Natera under pressure after Q4 miss and sell-siders&#39; modified outlooks; shares down 15% https://seekingalpha.com/news/3249615-natera-under-pressure-after-q4-miss-and-sell-siders-modified-outlooks-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3249615-natera-under-pressure-after-q4-miss-and-sell-siders-modified-outlooks-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249617\" data-ts=\"1488995132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249617-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a> <font color='green'>+19%</font>. AUXO <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PRSS' title='CafePress'>PRSS</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NATR' title='NATURE S SUNSHINE'>NATR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249617\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$GBT $MYOS $SPEX - Midday Gainers / Losers https://seekingalpha.com/news/3249617-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3249617-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249611\" data-ts=\"1488994077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLKS\" target=\"_blank\">FLKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249611-flex-pharma-meets-q4-revenue-consensus-slow-hotshot-ramp-disappoints-investors-shares-down-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flex Pharma meets Q4 revenue consensus, but slow HOTSHOT ramp disappoints investors; shares down 16%</a></h4><ul><li>Thinly traded nano cap Flex Pharma (<a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='red'>-15.6%</font>) is under pressure on more than double normal volume, albeit on turnover of only 162K shares. The company <a href=\"https://seekingalpha.com/pr/16764810-flex-pharma-reports-year-end-2016-financial-results\" target=\"_blank\">beat Q4 expectations</a>, but the slow sales ramp of muscle cramp-buster <a href=\"http://www.teamhotshot.com/our-science/#how-it-works\" target=\"_blank\">HOTSHOT </a>has investors hitting the sell button.</li><li>HOTSHOT, launched in June 2016, generated sales of only $299K in Q4 despite being sampled by over 20K athletes and 200 sports teams and the recruitment of \"ambassadors\" to endorse/promote the product.</li><li>The company says HOTSHOT works by stimulating sensory neurons in the mouth, stomach and esophagus which send impulses to the spinal cord that inhibit and overpower repetitive signals coming to and from cramped muscle.</li><li>Piper Jaffray's Joshua Schimmer maintains his Overweight rating but lowered the price target to $12 (300% upside) from $15.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249438-flex-pharma-beats-0_18-beats-revenue\" target=\"_blank\">Flex Pharma beats by $0.18, beats on revenue</a> (March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249611\" data-linked=\"Flex Pharma meets Q4 revenue consensus, but slow HOTSHOT ramp disappoints investors; shares down 16%\" data-tweet=\"$FLKS $SLRX - Flex Pharma meets Q4 revenue consensus, but slow HOTSHOT ramp disappoints investors; shares down 16% https://seekingalpha.com/news/3249611-flex-pharma-meets-q4-revenue-consensus-slow-hotshot-ramp-disappoints-investors-shares-down-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3249611-flex-pharma-meets-q4-revenue-consensus-slow-hotshot-ramp-disappoints-investors-shares-down-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249610\" data-ts=\"1488992477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249610-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MGPI' title='MGP Ingredients, Inc.'>MGPI</a> <font color='green'>+7%</font>. SPU <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249610\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MGPI $FTFT $ABAC-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3249610-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3249610-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249605\" data-ts=\"1488991975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249605-cellectar-bio-in-licenses-exclusive-rights-to-clr-131-in-multiple-myeloma-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar Bio in-licenses exclusive rights to CLR 131 in multiple myeloma; shares ahead 5%</a></h4><ul><li>Cellectar Biosciences (<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+4.9%</font>) perks up on average volume in response to its <a href=\"https://seekingalpha.com/pr/16764964-expanding-strategic-relationship-wisconsin-alumni-research-foundation-warf-cellectar\" target=\"_blank\">announcement </a>that it has formerly secured exclusive global rights to develop lead product candidate CLR 131 for multiple myeloma via a license agreement with shareholder Wisconsin Alumni Research Foundation &#40;WARF&#41;.</li><li>CEO Jim Caruso says, &ldquo;WARF is one of Cellectar&rsquo;s largest shareholders and remains a formidable partner. We believe this expansion of our relationship further solidifies our mutual commitment. Acquiring the remaining rights to the use of CLR 131 in multiple myeloma now provides us with complete control over the product&rsquo;s development and commercialization in all therapeutic areas.&rdquo;</li><li>CLR 131 is a&nbsp;<a href=\"http://cellectar.com/pdc-platform/\" target=\"_blank\">phospholipid ether-drug conjugate</a>&nbsp;that selectively delivers a cytotoxic payload to cancer cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249605\" data-linked=\"Cellectar Bio in-licenses exclusive rights to CLR 131 in multiple myeloma; shares ahead 5%\" data-tweet=\"$CLRB - Cellectar Bio in-licenses exclusive rights to CLR 131 in multiple myeloma; shares ahead 5% https://seekingalpha.com/news/3249605-cellectar-bio-in-licenses-exclusive-rights-to-clr-131-in-multiple-myeloma-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3249605-cellectar-bio-in-licenses-exclusive-rights-to-clr-131-in-multiple-myeloma-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249589\" data-ts=\"1488991251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249589-sa-contributor-qtr-still-bearish-on-herbalife-sees-over-40-downside-risk-shares-ease-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SA Contributor QTR still bearish on Herbalife, sees over 40% downside risk; shares ease 1%</a></h4><ul><li>Herbalife (<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='red'>-0.8%</font>) slips after SA Contributor Quoth the Raven Research published a bearish <a href=\"https://quoththeravenresearch.com/blog/\" target=\"_blank\">article </a>postulating that shares could drop below $30 (43% downside risk).</li><li>QTR cites likely downward pressure on the stock from the critical documentary <em>Betting on Zero</em> that will hit U.S. theaters this Friday. Additional factors weighing on the stock are stalling revenues in former high-growth China and the chance that activist investor Carl Icahn may unload his large stake before the film debuts (based on prior history).</li></ul><div class=\"tiny-share-widget\" data-id=\"3249589\" data-linked=\"SA Contributor QTR still bearish on Herbalife, sees over 40% downside risk; shares ease 1%\" data-tweet=\"$HLF - SA Contributor QTR still bearish on Herbalife, sees over 40% downside risk; shares ease 1% https://seekingalpha.com/news/3249589-sa-contributor-qtr-still-bearish-on-herbalife-sees-over-40-downside-risk-shares-ease-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3249589-sa-contributor-qtr-still-bearish-on-herbalife-sees-over-40-downside-risk-shares-ease-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>168&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249603\" data-ts=\"1488991072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIA\" target=\"_blank\">CIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249603-citizens-incminus-14-targeted-sa-contributor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citizens, Inc. -14%; targeted by SA contributor</a></h4><ul><li>\"Citizens (<a href='https://seekingalpha.com/symbol/CIA' title='Citizens, Inc.'>CIA</a> <font color='red'>-13.7%</font>) displays some characteristics that appear analogous to a Ponzi scheme,\" <a href=\"https://seekingalpha.com/article/4053091-citizens-egregious-stock-scheme\" target=\"_blank\">writes Seeking Alpha contributor Aurelius</a>.</li><li>Time could be running short, he says, as financials show many existing policyholders asking to be cashed out while new sales have plummeted, and longtime insiders have exited.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249603\" data-linked=\"Citizens, Inc. -14%; targeted by SA contributor\" data-tweet=\"$CIA - Citizens, Inc. -14%; targeted by SA contributor https://seekingalpha.com/news/3249603-citizens-incminus-14-targeted-sa-contributor?source=tweet\" data-url=\"https://seekingalpha.com/news/3249603-citizens-incminus-14-targeted-sa-contributor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249599\" data-ts=\"1488990960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPIX\" target=\"_blank\">IPIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249599-cellceutix-reports-encouraging-early-data-from-mid-stage-study-of-brilacidin-in-uc-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4%</a></h4><ul><li>Thinly traded nano cap Cellceutix (CTIX <font color='green'>+3.8%</font>) perks up on the heels of its <a href=\"https://seekingalpha.com/pr/16764881-cellceutix-releases-preliminary-efficacy-safety-data-interim-analysis-first-two-cohorts-phase\" target=\"_blank\">announcement </a>of positive interim results from a Phase 2 clinical trial assessing antibiotic Brilacidin to induce remission in patients with mild-to-moderate ulcerative colitis &#40;UC&#41;.</li><li>All 12 subjects in the first two cohorts achieved a beneficial response, while 50% achieved clinical remission at day 42. The remaining six patients achieved a partial response.</li><li>Brilacidin is a member of a new class of antibiotics called&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820767/\" target=\"_blank\">defensin-mimetics</a>, which are modeled after host defense proteins. These are the \"front line\" of defense in the human immune system. An oral rinse formulation is in Phase 2 development for the treatment of chemoradiation-associated oral mucositis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249599\" data-linked=\"Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4%\" data-tweet=\"$IPIX - Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4% https://seekingalpha.com/news/3249599-cellceutix-reports-encouraging-early-data-from-mid-stage-study-of-brilacidin-in-uc-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3249599-cellceutix-reports-encouraging-early-data-from-mid-stage-study-of-brilacidin-in-uc-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249597\" data-ts=\"1488990238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249597-global-blood-up-12-on-novo-nordisk-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood up 12% on Novo Nordisk interest</a></h4><ul><li>Global Blood Therapeutics (<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+12.2%</font>) jumps on a 4x surge in volume on the <a href=\"http://www.nasdaq.com/article/exclusivenovo-nordisk-in-bid-for-global-blood-therapeuticssources-20170308-00832\" target=\"_blank\">rumor </a>that insulin king Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='red'>-0.8%</font>) has approached it about a possible transaction.</li><li>GBT's lead product candidate is GBT440, a once-daily therapy to treat sickle cell disease.</li><li><strong>Update</strong>: Jacob Plieth <a href=\"https://twitter.com/JacobPlieth/status/839549000600682498\" target=\"_blank\">tweeted </a>that he heard a rumor that NVO's board has authorized a bid up to $45.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249597\" data-linked=\"Global Blood up 12% on Novo Nordisk interest\" data-tweet=\"$GBT $GBT $NVO - Global Blood up 12% on Novo Nordisk interest https://seekingalpha.com/news/3249597-global-blood-up-12-on-novo-nordisk-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3249597-global-blood-up-12-on-novo-nordisk-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249595\" data-ts=\"1488989799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249595-lack-of-insider-buying-buffalo-wild-wings-questioned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lack of insider buying at Buffalo Wild Wings questioned</a></h4><ul>     <li>Marcato Capital Management LP issues a biting report on the lack of insider buying at Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='red'>-0.5%</font>).</li>     <li>Marcatto on BWLD: &nbsp;\"Since its IPO in 2003, Buffalo Wild Wings' Board and Management team have sold the vast majority of all stock ever owned.&nbsp; In our view, this lack of long-term ownership has contributed to failures of governance and oversight, poor capital allocation discipline and the severe lack of urgency in navigating the difficult operating environment.&nbsp; Shareholders deserve a Board and management team that is willing to commit its own capital alongside them.\"</li>     <li>The firm holds a 5.6% position in the restaurant company.</li><li>If Buffalo Wild Wings issues a response to the Marcato charge it will be posted.</li>     <li>Shares of BWD have outperformed the USCF Restaurant Leaders ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/MENU' title='USCF Restaurant Leaders ETF'>MENU</a>)&nbsp;so far this year.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16765494-marcato-wants-know-buffalo-wild-wings-leadership-consistently-sold-bwld-stock-every\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3249595\" data-linked=\"Lack of insider buying at Buffalo Wild Wings questioned\" data-tweet=\"$BWLD $BWLD $MENU - Lack of insider buying at Buffalo Wild Wings questioned https://seekingalpha.com/news/3249595-lack-of-insider-buying-buffalo-wild-wings-questioned?source=tweet\" data-url=\"https://seekingalpha.com/news/3249595-lack-of-insider-buying-buffalo-wild-wings-questioned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249588\" data-ts=\"1488988853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249588-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NATR' title='NATURE S SUNSHINE'>NATR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249588\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$GBT $BLCM $MYOS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3249588-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3249588-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249583\" data-ts=\"1488988508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249583-h-and-r-block-grabs-tax-prep-market-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;R Block grabs tax prep market share</a></h4><ul> <li>H&amp;R Block (<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a> <font color='green'>+15.3%</font>) jets higher after the company <a href=\"https://seekingalpha.com/filing/3449792\" target=\"_blank\">reports</a> a strong start to the tax season.</li> <li>The company reeled some market share back in during FQ3 after several years of losses.</li> <li>\"The growth in market share is attributable to solid execution of an aggressive plan designed to change the trajectory of prior year client losses,\" says CEO Bill Cobb.</li> <li>H&amp;R also pulled tight on costs during the quarter amid a more promotional stance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249583\" data-linked=\"H&amp;R Block grabs tax prep market share\" data-tweet=\"$HRB - H&amp;R Block grabs tax prep market share https://seekingalpha.com/news/3249583-h-and-r-block-grabs-tax-prep-market-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3249583-h-and-r-block-grabs-tax-prep-market-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249581\" data-ts=\"1488988188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBSI\" target=\"_blank\">BBSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249581-external-factors-impact-barrett-business-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">External factors impact Barrett Business in Q4</a></h4><ul> <li>Barrett Business Services (<a href='https://seekingalpha.com/symbol/BBSI' title='Barrett Business Services, Inc.'>BBSI</a> <font color='red'>-12.1%</font>)&nbsp;trades sharply lower after the companyp <a href=\"https://seekingalpha.com/pr/16764398-bbsi-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">posts</a> Q4 numbers and FY17 guidance.</li> <li>Net income fell during the quarter, despite a 14% jump in revenue to $221.1M.</li> <li>\"Our same-customer sales were affected by severe weather in many of our markets, with some clients losing between 7 and 11 work days. Additionally, we saw the impact of a tightened labor market coupled with uncertainty during the time leading up to the election,\" notes CEO Michael Elich.</li> <li>Looking ahead, Barrett expects revenue to increase 16% this year.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3249297-barrett-business-reports-q4-results\" target=\"_blank\">Barrett Business reports Q4 results</a> (March 7)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249581\" data-linked=\"External factors impact Barrett Business in Q4\" data-tweet=\"$BBSI - External factors impact Barrett Business in Q4 https://seekingalpha.com/news/3249581-external-factors-impact-barrett-business-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3249581-external-factors-impact-barrett-business-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249577\" data-ts=\"1488987581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KODK\" target=\"_blank\">KODK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249577-weak-sales-trend-for-eastman-kodak\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak sales trend for Eastman Kodak</a></h4><ul> <li>Eastman Kodak (<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='red'>-9.9%</font>) falls after Q4 results throw a spotlight on the company's weak trend with consumer inkjet cartridge sales. Lower prices on digital plates within the print systems division was also a drag on revenue.</li> <li>Looking ahead, Eastman sees 2017 revenue of $1.4B to $1.5B and operational EBITDA of $130M to $145M.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3249320-eastman-kodak-reports-q4-results\" target=\"_blank\">Eastman Kodak reports Q4 results</a> (March 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3249577\" data-linked=\"Weak sales trend for Eastman Kodak\" data-tweet=\"$KODK - Weak sales trend for Eastman Kodak https://seekingalpha.com/news/3249577-weak-sales-trend-for-eastman-kodak?source=tweet\" data-url=\"https://seekingalpha.com/news/3249577-weak-sales-trend-for-eastman-kodak\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249576\" data-ts=\"1488987300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGPI\" target=\"_blank\">MGPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249576-plus-11-rip-for-mgp-ingredients-after-earnings-please\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">+11% rip for MGP Ingredients after earnings please</a></h4><ul> <li>MGP Ingredients (NASDAQ:<a href='https://seekingalpha.com/symbol/MGPI' title='MGP Ingredients, Inc.'>MGPI</a>) is <font color='green'>up 11%</font> after <a href=\"https://seekingalpha.com/pr/16764882-mgp-ingredients-reports-strong-fourth-quarter-2016-results\" target=\"_blank\">Q4</a> results arrive ahead of expectations.</li> <li>The company saw an increase in gross margin and net income, despite a 0.4% decline in sales during the quarter.</li> <li>\"We continue to migrate away from industrial alcohol, gross profit and margins expanded and operating income improved in both our Distillery Products and Ingredient Solutions segments,\" says CEO Gus Griffin.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3249464-mgp-ingredients-beats-0_09-revenue-line\" target=\"_blank\">MGP Ingredients beats by $0.09,  revenue in-line</a> (March 8)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249576\" data-linked=\"+11% rip for MGP Ingredients after earnings please\" data-tweet=\"$MGPI - +11% rip for MGP Ingredients after earnings please https://seekingalpha.com/news/3249576-plus-11-rip-for-mgp-ingredients-after-earnings-please?source=tweet\" data-url=\"https://seekingalpha.com/news/3249576-plus-11-rip-for-mgp-ingredients-after-earnings-please\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249575\" data-ts=\"1488987053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249575-qualcomm-and-microsoft-form-cloud-services-processor-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm and Microsoft form cloud services, processor collaboration</a></h4><ul><li>Qualcomm's (<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a> <font color='green'>+1.9%</font>) 10nm Centriq 2400 processors <a href=\"https://seekingalpha.com/pr/16765369-qualcomm-collaborates-microsoft-accelerate-cloud-services-10nm-qualcomm-centriq-2400-platform\" target=\"_blank\">will power certain cloud workloads</a> on Microsoft's (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='green'>+0.6%</font>) Azure platform, through a partnership that will extend across additional hardware, software and systems to come at points in the future.</li><li>Qualcomm, in a display of commitment to an ARM-based server&nbsp;ecosystem, joins the <a href=\"http://opencompute.org/\" target=\"_blank\">Open Compute Project</a>&nbsp;as a gold constituent, contributing the Centriq 2400 motherboard&nbsp;to the operation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249575\" data-linked=\"Qualcomm and Microsoft form cloud services, processor collaboration\" data-tweet=\"$QCOM $QCOM $MSFT - Qualcomm and Microsoft form cloud services, processor collaboration https://seekingalpha.com/news/3249575-qualcomm-and-microsoft-form-cloud-services-processor-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3249575-qualcomm-and-microsoft-form-cloud-services-processor-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249574\" data-ts=\"1488987051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249574-crude-futures-pares-losses-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures pares losses post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>:</li>     <li>Crude <strong>+8.2</strong><strong>M</strong> barrels vs. +1.97M consensus, +1.5M last week.</li>     <li>Gasoline <strong>-6.6</strong><strong>M</strong> barrels vs. -1.40M consensus, -0.50M last week.</li>     <li>Distillates <b>-2.7M</b>&nbsp;vs. -0.90M consensus, -0.90M last week.</li>     <li>Futures&nbsp;<font color='red'>-0.9%</font>&nbsp;to $52.66.</li>     <li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>,                       <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>,    <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>,           <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>,          <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>,    <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>,  <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>,          <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3249574\" data-linked=\"Crude futures pares losses post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures pares losses post inventory data https://seekingalpha.com/news/3249574-crude-futures-pares-losses-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3249574-crude-futures-pares-losses-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249569\" data-ts=\"1488986812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249569-wells-likes-bellicum-rates-outperform-shares-ahead-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells likes Bellicum, rates Outperform; shares ahead 19%</a></h4><ul><li>Thinly traded micro cap Bellicum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+19.4%</font>) is up on more than double normal volume on the heels of a bullish call from Wells Fargo who rates the stock Outperform with a price target range of $28 - 31 (113% upside from midpoint).</li><li>Wells cites the company's leading position in controllable cell therapies that have molecular switches that activate or eliminate therapeutic cells once inside the body. An \"off\" switch is particularly useful as a braking mechanism in CAR T therapies when they work too well. The massive immune response, called cytokine release syndrome or cytokine storm, can be life-threatening if left uncontrolled.</li><li>Source: StreetInsider</li></ul><div class=\"tiny-share-widget\" data-id=\"3249569\" data-linked=\"Wells likes Bellicum, rates Outperform; shares ahead 19%\" data-tweet=\"$BLCM - Wells likes Bellicum, rates Outperform; shares ahead 19% https://seekingalpha.com/news/3249569-wells-likes-bellicum-rates-outperform-shares-ahead-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3249569-wells-likes-bellicum-rates-outperform-shares-ahead-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249567\" data-ts=\"1488985610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSM\" target=\"_blank\">NSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249567-nationstar-mortgage-whacked-piper-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nationstar Mortgage whacked by Piper downgrade</a></h4><ul><li>The next several quarters will be challenging, says analyst Kevin Barker, noting the company is in the process of digesting a large Q3 sub-servicing acquisition, and prepping for the onboarding of $111B of new servicing.</li><li>Then there's originations, and 75% of Nationstar's (<a href='https://seekingalpha.com/symbol/NSM' title='Nationstar Mortgage Holdings'>NSM</a> <font color='red'>-7.3%</font>) volume in H2 last year came from refinancings. With higher rates, some see a 50% decline in refinancing this year. He expects NSM's origination pretax earnings to fall 38% in 2017.</li><li>Barker downgrades to Underweight with $15 price target (current price is $16.63).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3249567\" data-linked=\"Nationstar Mortgage whacked by Piper downgrade\" data-tweet=\"$NSM - Nationstar Mortgage whacked by Piper downgrade https://seekingalpha.com/news/3249567-nationstar-mortgage-whacked-piper-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3249567-nationstar-mortgage-whacked-piper-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249566\" data-ts=\"1488985398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHU\" target=\"_blank\">CHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249566-china-unicomplus-2_2-talks-ownership-reform-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Unicom +2.2% as it talks ownership reform again</a></h4><ul>   <li>China Unicom (NYSE:<a href='https://seekingalpha.com/symbol/CHU' title='China Unicom &#40;Hong Kong&#41; Limited'>CHU</a>) is <font color='green'>up 2.2%</font> in U.S. trading as it fans more talk about possible reforms of mixed ownership, prompting talk that <a href=\"http://blogs.barrons.com/asiastocks/2017/03/08/china-unicom-rising-on-mixed-ownership-reform-rumors-again\" target=\"_blank\">private investments could follow</a>.</li>    <li>That follows discussions from Unicom last fall about a mixed-ownership reform plan, in which the state-owned telecom might take strategic investment from the likes of Tencent, Alibaba and Baidu.</li>    <li>Reforming SOEs in China is moving slowly, though, Shuli Ren notes, adding that aside from mixed-ownership reform, China Unicom has another big catalyst ahead: a likely IPO for joint venture China Tower Co.</li>    <li>China Unicom closed <font color='green'>up 2.1%</font> in Hong Kong Wednesday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249566\" data-linked=\"China Unicom +2.2% as it talks ownership reform again\" data-tweet=\"$CHU - China Unicom +2.2% as it talks ownership reform again https://seekingalpha.com/news/3249566-china-unicomplus-2_2-talks-ownership-reform-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3249566-china-unicomplus-2_2-talks-ownership-reform-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249565\" data-ts=\"1488985373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249565-navistarplus-6-after-stifel-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar +6% after Stifel upgrades</a></h4><ul> <li>Shares of Navistar International (NYSE:<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>) move&nbsp;<font color='green'>up 5.55%</font>&nbsp;after the company lands an upgrade from Stifel Nicolaus to Hold from Sell.</li> <li>Stifel <a href=\"https://twitter.com/usratings/status/839452624483151872\" target=\"_blank\">boosts</a> its price target on Navistar by a buck to $24.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3249565\" data-linked=\"Navistar +6% after Stifel upgrades\" data-tweet=\"$NAV - Navistar +6% after Stifel upgrades https://seekingalpha.com/news/3249565-navistarplus-6-after-stifel-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3249565-navistarplus-6-after-stifel-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249563\" data-ts=\"1488985245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249563-kitov-pharma-out-licenses-lead-product-candidate-kitminus-302-in-south-korea-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov Pharma out-licenses lead product candidate KIT-302 in South Korea; shares ahead 13%</a></h4><ul><li>Kitov Pharmaceuticals Holdings (<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+12.8%</font>) inks an exclusive 10-year <a href=\"https://seekingalpha.com/pr/16765301-kitov-announces-license-agreement-kitminus-302-south-korea\" target=\"_blank\">license agreement </a>in South Korea with Kuhnil Pharmaceutical Co. Ltd., for lead product candidate KIT-302.</li><li>Under the terms of the deal, Kitov will eligible to receive milestone payments and double-digit royalties on net sales. Commercial launch is expected to commence in 2019.</li><li><a href=\"http://kitovpharma.com/products-2/kit-302/\" target=\"_blank\">KIT-302</a>&nbsp;is a combination drug that treats osteoporosis-related pain (celecoxib, branded as&nbsp;<a href=\"http://www.celebrex.com/?source=google&amp;HBX_PK=s_celebrex&amp;o=23040695|165564013|0&amp;skwid=43700007994682827&amp;sourcepoint=BS\" target=\"_blank\">Celebrex</a>&nbsp;by Pfizer) and hypertension (amlodipine besylate, branded as&nbsp;<a href=\"http://labeling.pfizer.com/ShowLabeling.aspx?id=562\" target=\"_blank\">Norvasc</a>).</li><li>Shares are up on almost double normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249563\" data-linked=\"Kitov Pharma out-licenses lead product candidate KIT-302 in South Korea; shares ahead 13%\" data-tweet=\"$KTOV - Kitov Pharma out-licenses lead product candidate KIT-302 in South Korea; shares ahead 13% https://seekingalpha.com/news/3249563-kitov-pharma-out-licenses-lead-product-candidate-kitminus-302-in-south-korea-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3249563-kitov-pharma-out-licenses-lead-product-candidate-kitminus-302-in-south-korea-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249561\" data-ts=\"1488984977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249561-bhp-billiton-bullish-on-oil-gas-hunts-for-oilfield-stakes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BHP Billiton, more bullish on oil than gas, hunts for oilfield stakes</a></h4><ul>     <li>BHP&nbsp;Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-2.6%</font>) is <a href=\"http://uk.reuters.com/article/uk-bhp-billiton-oil-idUKKBN16F0DB\" target=\"_blank\">on the lookout for more oil assets</a>, as its head of petroleum operations tells Reuters the company is more bullish on oil than gas over the next few years.</li>     <li>BHP's Steve Pastor says the company agrees with the International Energy Agency's outlook released this week that suggests demand will outstrip supply following a  sharp decline in investment in new production.</li>     <li>BHP is focused on the $9B Mad Dog phase 2 oil development in the deepwater Gulf of Mexico, drilling the Trion prospect with Pemex, and exploring off Trinidad and Tobago, while looking for more high quality oil assets, Pastor says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249561\" data-linked=\"BHP Billiton, more bullish on oil than gas, hunts for oilfield stakes\" data-tweet=\"$BHP - BHP Billiton, more bullish on oil than gas, hunts for oilfield stakes https://seekingalpha.com/news/3249561-bhp-billiton-bullish-on-oil-gas-hunts-for-oilfield-stakes?source=tweet\" data-url=\"https://seekingalpha.com/news/3249561-bhp-billiton-bullish-on-oil-gas-hunts-for-oilfield-stakes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249558\" data-ts=\"1488984380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPN\" target=\"_blank\">CAPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249558-capnia-completes-merger-essentialis-shares-ahead-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capnia completes merger with Essentialis; shares ahead 17%</a></h4><ul><li>Thinly traded nano cap Capnia (<a href='https://seekingalpha.com/symbol/CAPN' title='Capnia'>CAPN</a>) <a href=\"https://seekingalpha.com/pr/16764817-capnia-completes-merger-essentialis-creating-rare-disease-therapeutics-company\" target=\"_blank\">completes its merger </a>with privately held Essentialis, announced in December.</li><li>Capnia's lead product candidate is Phase 2/3-stage diazoxide choline controlled-release &#40;DCCR&#41;, a once-daily oral tablet to treat Prader-Willi syndrome.</li><li>Shares are up&nbsp;<font color='green'>17%</font>&nbsp;on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3232528-capnia-merge-essentialis-advance-pws-drug\" target=\"_blank\">Capnia to merge with Essentialis, advance PWS drug</a> (Dec. 27, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249558\" data-linked=\"Capnia completes merger with Essentialis; shares ahead 17%\" data-tweet=\"$CAPN - Capnia completes merger with Essentialis; shares ahead 17% https://seekingalpha.com/news/3249558-capnia-completes-merger-essentialis-shares-ahead-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3249558-capnia-completes-merger-essentialis-shares-ahead-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249557\" data-ts=\"1488983947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTLA\" target=\"_blank\">NTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249557-intellia-boosts-gene-editing-efficiency-lnp-technology-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellia boosts gene editing efficiency with LNP technology; shares up 9%</a></h4><ul><li>Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+9.1%</font>) <a href=\"https://seekingalpha.com/pr/16764883-intellia-therapeutics-demonstrates-pioneering-crispr-cas9-genome-editing-efficiency-data\" target=\"_blank\">reports updated data</a> from an animal model study that showed increased levels of genome editing efficiency with CRISPR/Cas9 when combined with its lipid nanoparticle &#40;LNP&#41; technology. In mouse liver, a single administration produced a 97% reduction in serum transthyretin &#40;TTR&#41; protein implying gene editing efficiency of 70%. The data are being presented today at Cowen's 37th Annual Healthcare Conference in Boston.</li><li>EVP, R&amp;D John Leonard, M.D. says, &ldquo;These results are extremely promising, as they demonstrate compelling activity with lipid nanoparticles observed in the liver following a single dose. We are excited by the extent of the effect, which confirms the power of CRISPR/Cas9 for potential therapeutic uses. These high levels of gene editing are the result of Intellia&rsquo;s effort to identify highly efficient delivery of CRISPR/Cas9 using lipid nanoparticles. The data advance our efforts as we look to transform the way we treat disease.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3249557\" data-linked=\"Intellia boosts gene editing efficiency with LNP technology; shares up 9%\" data-tweet=\"$NTLA - Intellia boosts gene editing efficiency with LNP technology; shares up 9% https://seekingalpha.com/news/3249557-intellia-boosts-gene-editing-efficiency-lnp-technology-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3249557-intellia-boosts-gene-editing-efficiency-lnp-technology-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249547\" data-ts=\"1488983189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249547-cienaminus-3-pre-market-q1-2017-off-estimates-q2-revenue-forecast-midpoint-over\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ciena -3% pre-market; Q1 2017 off estimates, Q2 revenue forecast midpoint over</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3249445-ciena-misses-0_03-misses-revenue\" target=\"_blank\">Q1 2017 results</a></strong> &ndash; revenue $621.5M (+8.4% Y/Y,&nbsp;<font color='red'>$10.79M below estimates</font>), EPS $0.26 (<font color='red'>$0.03 below estimates</font>), net income $38.4M (vs. $25.2M Y/Y)</li><li><strong>Q2 2017 projections</strong> &ndash; revenue $680M-$710M (<a href=\"https://finance.yahoo.com/quote/CIEN/analysts?p=CIEN\" target=\"_blank\">consensus $690.72M</a>), gross margin mid-40s percentage range, operating expense $240M</li><li><strong>Pre-market</strong> &ndash; (NASDAQ:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) $25.35</li><li><a href=\"https://seekingalpha.com/pr/16764815-ciena-reports-fiscal-first-quarter-2017-financial-results\" target=\"_blank\">Press release</a> / <a href=\"http://investor.ciena.com/phoenix.zhtml?c=99134&amp;p=irol-EventDetails&amp;EventId=5247007\" target=\"_blank\">conference call</a> / <a href=\"https://seekingalpha.com/filing/3450964\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249547\" data-linked=\"Ciena -3% pre-market; Q1 2017 off estimates, Q2 revenue forecast midpoint over\" data-tweet=\"$CIEN - Ciena -3% pre-market; Q1 2017 off estimates, Q2 revenue forecast midpoint over https://seekingalpha.com/news/3249547-cienaminus-3-pre-market-q1-2017-off-estimates-q2-revenue-forecast-midpoint-over?source=tweet\" data-url=\"https://seekingalpha.com/news/3249547-cienaminus-3-pre-market-q1-2017-off-estimates-q2-revenue-forecast-midpoint-over\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249546\" data-ts=\"1488983136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249546-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/XTLB' title='XTL Biopharmaceuticals Ltd.'>XTLB</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>&nbsp;<font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a>&nbsp;<font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a>&nbsp;<font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>&nbsp;<font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>&nbsp;<font color='green'>+7%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a>&nbsp;<font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>&nbsp;<font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TSL' title='Trina Solar Limited'>TSL</a>&nbsp;<font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/LAND' title='Gladstone Land'>LAND</a>&nbsp;<font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249546\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$PRKR $KTOV $XTLB - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3249546-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3249546-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249541\" data-ts=\"1488982801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAND\" target=\"_blank\">LAND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249541-gladstone-landminus-5_5-after-pricing-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gladstone Land -5.5% after pricing secondary</a></h4><ul><li>Gladstone Land (NASDAQ:<a href='https://seekingalpha.com/symbol/LAND' title='Gladstone Land'>LAND</a>) expects about $18M in net proceeds after pricing a 1.68M share capital raise at $11.35 each. That number could go up should the underwriters exercise their 252K share greenshoe.</li><li>The offering size was upsized a bit - it was originally for just 1.4M shares.</li><li>The stock's&nbsp;<font color='red'>down 5.5%</font>&nbsp;premarket to $11.10.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249335-gladstone-land-minus-3_4-percent-capital-raise\" target=\"_blank\">Gladstone Land -3.4% on capital raise</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249541\" data-linked=\"Gladstone Land -5.5% after pricing secondary\" data-tweet=\"$LAND - Gladstone Land -5.5% after pricing secondary https://seekingalpha.com/news/3249541-gladstone-landminus-5_5-after-pricing-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3249541-gladstone-landminus-5_5-after-pricing-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249539\" data-ts=\"1488982685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOJA\" target=\"_blank\">BOJA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249539-soft-guidance-trips-up-bojangles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soft guidance trips up Bojangles&#39;</a></h4><ul> <li>Bojangles' (NASDAQ:<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a>) <a href=\"https://seekingalpha.com/pr/16764424-bojangles-inc-reports-financial-results-fourth-fiscal-quarter-fiscal-year-2016\" target=\"_blank\">expects</a> FY17 revenue of $560M to $569M vs. $588M consensus and EPS of $0.87 to $0.90 vs. $1.01 consensus. The conservative guidance has a number of analysts puzzled.</li> <li>The restaurant operator reports system-wide comparable restaurant sales rose 2.4% in Q4. Restaurant contribution of a percentage of sales increased 70 bps to 19.6%. Those marks are expected to get worse, according to the soft outlook from BOJA management.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249308-bojangles-beats-0_07-misses-revenue\" target=\"_blank\">Bojangles beats by $0.07, misses on revenue</a> (March 7)</li> <li>BOJA <font color='red'>-3.80%</font> premarket to $19.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3249539\" data-linked=\"Soft guidance trips up Bojangles&#39;\" data-tweet=\"$BOJA - Soft guidance trips up Bojangles&#39; https://seekingalpha.com/news/3249539-soft-guidance-trips-up-bojangles?source=tweet\" data-url=\"https://seekingalpha.com/news/3249539-soft-guidance-trips-up-bojangles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249538\" data-ts=\"1488982580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCRX\" target=\"_blank\">OCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249538-analysis-of-mid-stage-data-showed-oceras-lead-product-candidate-lowered-ammonia-levels-faster\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Further analysis of mid-stage data showed Ocera&#39;s lead product candidate lowered ammonia levels faster than standard of care in HE patients; shares up 51% premarket</a></h4><ul><li>Nano cap Ocera Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OCRX' title='Ocera Therapeutics, Inc.'>OCRX</a>) rockets&nbsp;<font color='green'>51%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16765034-ocera-announce-additional-encouraging-results-phase-2b-stop-study-iv-ocrminus-002-patients\" target=\"_blank\">announcement </a>of positive data from its continued analysis of its Phase 2b STOP-HE study assessing lead product candidate OCR-002 (ornithine phenylacetate) in hospitalized patients with hepatic encephalopathy &#40;HE&#41;. The results will be presented today at Cowen's 37th Annual Healthcare Conference.</li><li>Shares plummeted in January after the company announced that STOP-HE failed to achieve its primary endpoint. Specifically, OCR-002 failed to beat placebo as measured by time to improvement in HE symptoms.</li><li>A further analysis of the results showed treatment with OCR-002 rapidly and safely lowered ammonia in HE patients to levels associated with clinical improvement. The company intends to advance OCR-002 into Phase 3 development.</li><li>Ornithine phenylacetate is an ammonia scavenger that reduces excess ammonia in patients with liver cirrhosis and acute liver failure. Elevated ammonia causes swelling in the brain producing symptoms of HE.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238670-oceras-lead-product-candidate-flunks-mid-stage-study-shares-plummet-59-percent-premarket\" target=\"_blank\">Ocera's lead product candidate flunks mid-stage HE study; shares plummet 59% premarket</a> (Jan. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249538\" data-linked=\"Further analysis of mid-stage data showed Ocera&#39;s lead product candidate lowered ammonia levels faster than standard of care in HE patients; shares up 51% premarket\" data-tweet=\"$OCRX - Further analysis of mid-stage data showed Ocera&#39;s lead product candidate lowered ammonia levels faster than standard of care in HE patients; shares up 51% premarket https://seekingalpha.com/news/3249538-analysis-of-mid-stage-data-showed-oceras-lead-product-candidate-lowered-ammonia-levels-faster?source=tweet\" data-url=\"https://seekingalpha.com/news/3249538-analysis-of-mid-stage-data-showed-oceras-lead-product-candidate-lowered-ammonia-levels-faster\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249536\" data-ts=\"1488982505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249536-another-big-day-for-financials-on-tap-after-adp-number\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another big day for financials on tap after ADP number</a></h4><ul><li>The ADP <a href=\"https://seekingalpha.com/news/3249529-march-rate-hike-odds-move-100-percent\" target=\"_blank\">reported a whopping</a> 298K jobs added in February, the third-best print of the recovery.</li><li>Fixed-income players have responded by sending the yield on the 10-year Treasury up 5.5 basis points to 2.573, and the odds of a rate hike next week to 100%.</li><li>Yield-starved financials continue to get less so by the day. Premarket: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>&nbsp;<font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>&nbsp;<font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>&nbsp;<font color='green'>+1.9%</font>, <a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>&nbsp;<font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>&nbsp;<font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>&nbsp;<font color='green'>+1.6%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3249536\" data-linked=\"Another big day for financials on tap after ADP number\" data-tweet=\"$BAC $XLF $KRE - Another big day for financials on tap after ADP number https://seekingalpha.com/news/3249536-another-big-day-for-financials-on-tap-after-adp-number?source=tweet\" data-url=\"https://seekingalpha.com/news/3249536-another-big-day-for-financials-on-tap-after-adp-number\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249533\" data-ts=\"1488982207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249533-skyworks-solutions-upgraded-to-outperform-mizuho-securities-initiated-likewise-wells-fargo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks Solutions upgraded to Outperform at Mizuho Securities, initiated likewise at Wells Fargo</a></h4><ul><li>Raising target from $80 to $110, <a href=\"http://www.streetinsider.com/Analyst+Comments/Mizuho+Securities+Upgrades+Skyworks+Solutions+%28SWKS%29+to+Outperform/12643403.html\" target=\"_blank\">analyst Vijay Rakesh</a> (Mizuho Securities) notes sound execution and positioning into the forthcoming Apple iPhone cycle and revived efforts out of Samsung Electronics, as well as among the altogether healthy China handset market. Rating from Neural prior.</li><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Starts+Skyworks+Solutions+%28SWKS%29+at+Outperform/12644204.html\" target=\"_blank\">Wells Fargo</a>, setting valuation range at $100-$118, attributes positives to be strength in growth over recent years, ongoing content increase opportunity as relates to wireless handsets, product diversification, steady gross margin and overall financial model. Risks observed include customer, as well as segment concentration, competition in the radio frequency component sector, absence of internal bulk acoustic wave filter manufacturing and a fragmented \"Broad Markets\" unit.</li><li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) $96.15,&nbsp;<font color='green'>+1.16%</font>&nbsp;pre-market.</li><li>Earlier this week (March 6, 2017): <a href=\"https://seekingalpha.com/news/3248883-skyworks-solutions-target-raised-105-canaccord-genuity\" target=\"_blank\">Skyworks Solutions target raised to $105 at Canaccord Genuity</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3249533\" data-linked=\"Skyworks Solutions upgraded to Outperform at Mizuho Securities, initiated likewise at Wells Fargo\" data-tweet=\"$SWKS - Skyworks Solutions upgraded to Outperform at Mizuho Securities, initiated likewise at Wells Fargo https://seekingalpha.com/news/3249533-skyworks-solutions-upgraded-to-outperform-mizuho-securities-initiated-likewise-wells-fargo?source=tweet\" data-url=\"https://seekingalpha.com/news/3249533-skyworks-solutions-upgraded-to-outperform-mizuho-securities-initiated-likewise-wells-fargo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249525\" data-ts=\"1488981568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADDYY\" target=\"_blank\">ADDYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249525-adidas-bringing-game-to-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adidas bringing its A-game to the U.S.</a></h4><ul> <li>The sports apparel sector has its eyes on Adidas&nbsp;(<a href='https://seekingalpha.com/symbol/ADDYY' title='adidas AG ADR'>OTCQX:ADDYY</a>, <a href='https://seekingalpha.com/symbol/ADDDF' title='adidas AG'>OTCQX:ADDDF</a>) as the company continues to post improved growth numbers and sets aggressive targets.</li><li>FY16 results came in strong and guidance for 2017 was ahead of consensus estimates. Looking even further ahead, Adidas forecasts it will generate revenue of &euro;25B to &euro;27B by 2020 and hit an operating margin of 11%.</li> <li>The German company plans to invest heavily in the U.S. and keep a sharper focus on the lifestyle market, while pulling away from hockey and golf. CEO Kaspar Rorsted also talked up the potential of Adidas using its fast-fashion tilt to bring trend-on products to the market quicker.</li> <li><a href=\"http://edge.media-server.com/m/p/s7qpmcnj\" target=\"_blank\">Adidas presentation webcast</a></li> <li>Shares of Adidas are <font color='green'>up 7.70%</font> in Frankfurt trading.</li><li>What to watch:&nbsp;The aggressive moves by Adidas could impact Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) and Under Armour (NYSE:<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249525\" data-linked=\"Adidas bringing its A-game to the U.S.\" data-tweet=\"$ADDYY $ADDYY $ADDDF - Adidas bringing its A-game to the U.S. https://seekingalpha.com/news/3249525-adidas-bringing-game-to-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3249525-adidas-bringing-game-to-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249524\" data-ts=\"1488981542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCMP\" target=\"_blank\">SCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249524-sucampo-up-7-premarket-on-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sucampo up 7% premarket on Q4 beat</a></h4><ul><li>Sucampo Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>) <a href=\"https://seekingalpha.com/pr/16764786-sucampo-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Q4 results </a>($M): Total Revenues: 73.0 (+31.8%); AMITIZA Sales: 39.4 (+39.7%), AMITIZA Royalty: 26.3 (+14.8%).</li><li>Net Income: 15.3 (+50.0%); Non-GAAP Net Income: 30.7 (+59.9%); EPS: 0.34 (+47.8%); Non-GAAP EPS: 0.68 (+58.1%).</li><li>AMITIZA prescriptions:&nbsp;383.9K (-2%).</li><li><strong>2017 Guidance</strong>: Revenues: $220M - 230M; Non-GAAP Net Income: $80M - 90M; Non-GAAP EPS: $1.35 - 1.50; Non-GAAP EBITDA: $145M - 155M.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on average volume.</li><li>Previously:&nbsp;<a href=\"https://seekingalpha.com/news/3249428-sucampo-beats-0_20-beats-revenue\" target=\"_blank\">Sucampo beats by $0.20, beats on revenue</a>&nbsp;(March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3249524\" data-linked=\"Sucampo up 7% premarket on Q4 beat\" data-tweet=\"$SCMP - Sucampo up 7% premarket on Q4 beat https://seekingalpha.com/news/3249524-sucampo-up-7-premarket-on-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3249524-sucampo-up-7-premarket-on-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249512\" data-ts=\"1488980613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249512-fda-accepts-allergans-application-for-expanded-use-of-antipsychotic-med-vraylar-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Allergan&#39;s application for expanded use of antipsychotic med Vraylar; shares up 2% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16764975-fda-accepts-supplemental-new-drug-application-snda-vraylar-cariprazine\" target=\"_blank\">accepts for review</a> Allergan's (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) supplemental New Drug Application (sNDA) seeking the addition of new clinical data to the label of VRAYLAR (cariprazine) as maintenance therapy in adults with schizophrenia.</li><li>The data includes results from a Phase 3 study, RG-MD-06, that showed treatment with VRAYLAR significantly delayed time to relapse compared to placebo.</li><li>The agency's action date is not provided, but it should be sometime in November.</li><li><a href=\"http://www.vraylar.com/schizophrenia\" target=\"_blank\">VRAYLAR </a>is currently approved in the U.S. for the acute treatment of manic or mixed episodes of Bipolar I Disorder and the treatment of schizophrenia in adults.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249512\" data-linked=\"FDA accepts Allergan&#39;s application for expanded use of antipsychotic med Vraylar; shares up 2% premarket\" data-tweet=\"$AGN - FDA accepts Allergan&#39;s application for expanded use of antipsychotic med Vraylar; shares up 2% premarket https://seekingalpha.com/news/3249512-fda-accepts-allergans-application-for-expanded-use-of-antipsychotic-med-vraylar-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3249512-fda-accepts-allergans-application-for-expanded-use-of-antipsychotic-med-vraylar-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249500\" data-ts=\"1488980271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRKR\" target=\"_blank\">PRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249500-parkervisionplus-44_8-pre-market-subsequent-favorable-ruling-in-qualcomm-patent-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ParkerVision +44.8% pre-market subsequent favorable ruling in Qualcomm patent case</a></h4><ul><li>The Patent Trial and Appeal Board [PTAB] has&nbsp;<a href=\"https://seekingalpha.com/pr/16764820-latest-ptab-ipr-rulings-increase-favorable-decisions-parkervision\" target=\"_blank\">issued decisions</a> regarding Qualcomm's petitions for inter parties review against certain ParkerVision patents in favor of the latter for six out of ten petitions initially filed.</li><li>Consequently, at the present time,&nbsp;no additional inter parties review disputing ParkerVision patents are under consideration at the PTAB.</li><li>ParkerVision (<a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a>) $3.75.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249500\" data-linked=\"ParkerVision +44.8% pre-market subsequent favorable ruling in Qualcomm patent case\" data-tweet=\"$PRKR - ParkerVision +44.8% pre-market subsequent favorable ruling in Qualcomm patent case https://seekingalpha.com/news/3249500-parkervisionplus-44_8-pre-market-subsequent-favorable-ruling-in-qualcomm-patent-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3249500-parkervisionplus-44_8-pre-market-subsequent-favorable-ruling-in-qualcomm-patent-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249505\" data-ts=\"1488980107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LADR\" target=\"_blank\">LADR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249505-ladder-capital-down-5-backers-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ladder Capital down 5% as backers sell</a></h4><ul><li>A number of funds <a href=\"https://seekingalpha.com/pr/16764949-ladder-capital-corp-announces-pricing-secondary-public-offering-class-common-stock\" target=\"_blank\">priced a 3M share secondary</a>, raising gross proceeds of about $42M (suggesting an offering price of $14). The company will not receive any money from the sale.</li><li><a href='https://seekingalpha.com/symbol/LADR' title='Ladder Capital Corp'>LADR</a><font color='red'> -5.1%</font>&nbsp;to $14.15 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249505\" data-linked=\"Ladder Capital down 5% as backers sell\" data-tweet=\"$LADR - Ladder Capital down 5% as backers sell https://seekingalpha.com/news/3249505-ladder-capital-down-5-backers-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3249505-ladder-capital-down-5-backers-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249502\" data-ts=\"1488979778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERX\" target=\"_blank\">KERX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249502-fda-to-review-keryx-bios-application-for-expanded-use-of-auryxia-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA to review Keryx Bio&#39;s application for expanded use of Auryxia; shares ahead 5% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16764884-keryx-biopharmaceuticals-announces-u-s-fda-filing-acceptance-supplemental-new-drug\" target=\"_blank\">accepts for review</a> Keryx Biopharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/KERX' title='Keryx Biopharmaceuticals, Inc.'>KERX</a>) supplemental New Drug Application (sNDA) seeking approval for the use of Auryxia (ferric citrate) to treat iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease. The agency's action date is November 6.</li><li>The FDA approved Auryxia in September 2014 to control serum phosphorus levels in patients with chronic kidney disease on dialysis.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249502\" data-linked=\"FDA to review Keryx Bio&#39;s application for expanded use of Auryxia; shares ahead 5% premarket\" data-tweet=\"$KERX - FDA to review Keryx Bio&#39;s application for expanded use of Auryxia; shares ahead 5% premarket https://seekingalpha.com/news/3249502-fda-to-review-keryx-bios-application-for-expanded-use-of-auryxia-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3249502-fda-to-review-keryx-bios-application-for-expanded-use-of-auryxia-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249495\" data-ts=\"1488979370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRA\" target=\"_blank\">VRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249495-vera-bradleyminus-13_6-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley -13.6% post Q4 results</a></h4><ul>     <li>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a>)&nbsp;reports comparable sales declined 9.5% in <a href=\"https://seekingalpha.com/pr/16764984-vera-bradley-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Q4</a> due to&nbsp;declines in store and e-commerce traffic.</li>     <li>Direct segment revenue decreased 3.6% to $108.9M.</li>     <li>Indirect segment revenue fell 36.9% to $26M.</li>     <li>E-commerce sales slipped 6.5% Y/Y.</li>     <li>Gross margin rate down 250 bps to 55.7% due to increased promotional activity at the Company&rsquo;s factory outlet stores.</li>     <li>Adjusted SG&amp;A expense rate rose 430 bps to 44.6%.</li>     <li>Adjusted operating margin rate dropped 710 bps to 11.3%.</li>     <li>Inventory -7.1% Y/Y to $96.55M.</li>     <li><b>Q1 Guidance</b>: Net revenues: $94M to $99M; Gross margin rate: 55% to 55.5%; SG&amp;A expense rate: 61.1% to 63.3%; Tax rate: 25%; Diluted EPS: -$0.11 to -$0.14; Weighted-average shares outstanding: 36.2M; Inventory: $100M to $110M.</li>     <li><b>FY2018 Guidance</b>:&nbsp;Net revenues: $460M to $480M; Gross margin rate: 56% to 56.5%; SG&amp;A expense rate: 50.8% to 51.3%; Tax rate: 38%; Diluted EPS: $0.40 to $0.50; Weighted-average shares outstanding: 35.8M; Capex: ~$10M to $15M.</li><li>VRA<font color='red'> -13.63%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3249495\" data-linked=\"Vera Bradley -13.6% post Q4 results\" data-tweet=\"$VRA - Vera Bradley -13.6% post Q4 results https://seekingalpha.com/news/3249495-vera-bradleyminus-13_6-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3249495-vera-bradleyminus-13_6-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249492\" data-ts=\"1488978958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSG\" target=\"_blank\">TSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249492-amaya-on-move-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amaya on the move again</a></h4><ul> <li>Amaya Holdings (AYA) is extending on yesterday's 5.65% gain (+5.75% in Toronto) in early trading.</li> <li>The rally appears to be tied to yesterday's <a href=\"http://www.reuters.com/article/brief-david-baazov-says-disposed-of-owne-idUSFWN1GK0UV\" target=\"_blank\">disclosure</a> that David Baazov sold 7M shares of Amaya stock at C$19 per share to lwoer his stake to 12.1%.</li> <li>Amaya is <font color='green'>up 1.67%</font> premarket to $15.20 on the Nasdaq.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3249492\" data-linked=\"Amaya on the move again\" data-tweet=\"$TSG - Amaya on the move again https://seekingalpha.com/news/3249492-amaya-on-move-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3249492-amaya-on-move-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3249489\" data-ts=\"1488978638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3249489-health-insurance-innovations-down-13-premarket-on-pending-stock-sale-founder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations down 13% premarket on pending stock sale by founder</a></h4><ul><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a>) slumps&nbsp;<font color='red'>13%&nbsp;</font>premarket on light volume in response to its<a href=\"http://investor.hiiquote.com/releasedetail.cfm?ReleaseID=1016326\" target=\"_blank\"> planned secondary public offering</a> of Class A common stock, all of which will be sold by entities controlled by founder Michael Kosloske. The company will receive no proceeds from the sale.</li><li>Yesterday's close was $17.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3249489\" data-linked=\"Health Insurance Innovations down 13% premarket on pending stock sale by founder\" data-tweet=\"$HIIQ - Health Insurance Innovations down 13% premarket on pending stock sale by founder https://seekingalpha.com/news/3249489-health-insurance-innovations-down-13-premarket-on-pending-stock-sale-founder?source=tweet\" data-url=\"https://seekingalpha.com/news/3249489-health-insurance-innovations-down-13-premarket-on-pending-stock-sale-founder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}